SAN DIEGO, Oct 18, 2021 – Coastar Therapeutics Inc., an emerging biotech company focused on biological payload delivery technology for cancer immunotherapy and gene therapy, today announced that it is attending the 6th Oncolytic Virotherapy Summit on October 26-28 in Boston, Massachusetts and the International Oncolytic Virus Conference (IOVC) on November 5-7 in Sedona, Arizona.

“We are truly excited to meet our colleagues in oncolytic virotherapy research from around the world at these two conferences,” said Eddie Y. Chung, CEO of Coastar Therapeutics, “Our cell membrane coating technology will offer great protection of their oncolytic viruses against immune clearance, which will result in better efficacy, more applications, lower toxicity and lower cost.”

“We are closely following the latest science in oncolytic virotherapy. In the last five years there has been tremendous growth in oncolytic viruses, and there are now hundreds of clinical trials around the world”, said Han L. Lim, CSO of Coastar Therapeutics.

“Coastar looks forwards to form new partnerships with companies and institutions who are developing new oncolytic viruses,” said Chongyang Luo, head of business development of Coastar Therapeutics.

Coastar Therapeutics has developed an innovative cell membrane coating technology platform that enables a wide range of biological payloads to avoid immune clearance and be successfully delivered to disease sites. The technology will lead to increased efficacy, reduced toxicity, lower cost and more applications in cancers and other diseases.

ABOUT COASTAR THERAPEUTICS

Coastar Therapeutics Inc., is a San Diego based company developing biological payload delivery technologies for cancer and gene therapies. The company’s proprietary ENHEnS^TM technology can coat cell membranes on biological payloads to help them evade recognition and clearance by the immune system and be successfully delivered to tumor or other disease sites (YouTube link: https://youtu.be/4BMdkyJ09nM). The company is developing coatings for oncolytic viruses in cancer immunotherapy as well as for AAV in gene therapy.